Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:STTK

Shattuck Labs Q3 2026 Earnings Date & Estimates

Shattuck Labs logo
$5.33 -0.16 (-2.91%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$5.32 0.00 (-0.09%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Shattuck Labs is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Shattuck Labs in Q3 2026

Shattuck Labs is expected to post earnings of -$0.10 per share on revenue of $0.03 million. In the same quarter a year earlier Shattuck Labs reported -$0.14 per share on revenue of $1.00 million. Shattuck Labs last reported on August 11, 2026, posting -$0.12 per share and beating the -$0.1241 consensus estimate. Shattuck Labs has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.10
Expected Revenue
$0.03 million
Prior-Year EPS
-$0.14
Prior-Year Revenue
$1.00 million
Expected Revenue Growth
-96.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.12 (Beat by +$0.0041)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Shattuck Labs Q3 2026 Earnings FAQ

Shattuck Labs (NASDAQ:STTK) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Shattuck Labs' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Shattuck Labs to post earnings of -$0.10 per share for Q3 2026.

The consensus revenue estimate for Shattuck Labs is $0.03 million for Q3 2026.

Shattuck Labs Earnings Headlines

Shattuck Labs (NASDAQ:STTK) vs. Exicure (NASDAQ:XCUR) Critical Contrast
October 13 at 8:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31115362
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
October 13 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379616/0/en/shattuck-labs-announces-two-poster-presentations-at-ueg-week-2026.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
 |  Stansberry Research (Ad)
UBS Initiates Shattuck Labs at Buy With $17 Price Target
October 12 at 4:10 PM  |  marketscreener.comM
Shattuck Labs (STTK) Receives a Buy from Leerink Partners
October 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/STTK-Q/pressreleases/4927856/shattuck-labs-sttk-receives-a-buy-from-leerink-partners/
Needham & Company LLC Forecasts Strong Price Appreciation for Shattuck Labs (NASDAQ:STTK) Stock
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083693
See More Shattuck Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shattuck Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shattuck Labs and other key companies, straight to your email.

About Shattuck Labs

Shattuck Labs (NASDAQ:STTK) is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to create biologic medicines that combine immune checkpoint blockade with immune-cell activation in a single therapeutic construct.

Shattuck’s pipeline has included investigational ARC fusion proteins intended to alter the tumor microenvironment and stimulate immune responses against cancer cells. Its lead programs have been evaluated in clinical studies involving advanced solid tumors and hematologic malignancies, including research into therapies targeting CD47 and CD40 ligand pathways. The company continues to assess applications of its platform across oncology and potentially other disease areas.

Shattuck Labs was founded in 2016 and maintains operations in the United States. The company is led by Taylor Schreiber, M.D., Ph.D., who serves as president and chief executive officer. Its therapies remain investigational and are subject to clinical testing and regulatory review.

View Shattuck Labs Profile
Earnings Tools